Methacholine Challenge Test

It measures airway hyperresponsiveness, how much the airways narrow in response to an inhaled substance called methacholine, a medication that causes airway smooth muscle to contract. People with hyperreactive airways, a hallmark of asthma, tend to narrow their airways at lower doses than people without asthma.

Spirometry performed between symptomatic periods can look completely normal in someone with asthma, since airflow limitation in asthma is often variable rather than constant. A methacholine challenge test is designed specifically to reveal airway hyperresponsiveness even when resting airflow looks normal, which is why it is typically ordered after a normal or borderline spirometry result when asthma is still suspected.

You inhale nebulized methacholine in gradually increasing concentrations, with your FEV1 measured by spirometry after each dose. The test continues until either your FEV1 drops by a defined threshold or you reach the highest concentration in the protocol without a significant drop, at which point the test is stopped.

PC20 stands for the provocative concentration of methacholine that causes a 20 percent fall in FEV1 from your baseline value. By common convention, a lower PC20 (methacholine causing a significant drop at a low concentration) indicates more pronounced airway hyperresponsiveness, while a higher PC20, or no significant drop at all, is reassuring against clinically significant hyperresponsiveness. The exact numeric cutoffs used to classify a result as positive, borderline, or negative can vary somewhat depending on the specific testing protocol and dosing method used by a given lab.

Not automatically. A positive result supports the presence of airway hyperresponsiveness, which is a hallmark of asthma, but airway hyperresponsiveness can also occur with other conditions, including allergic rhinitis, recent respiratory infections, and some other airway diseases. Your physician interprets a positive result alongside your symptoms and history rather than treating it as a diagnosis by itself.

In many clinical situations, yes. The methacholine challenge test has strong negative predictive value, meaning a negative result (no significant drop in FEV1 even at the highest tested concentration) makes a current asthma diagnosis considerably less likely. This is one of the main reasons the test is ordered, to help rule asthma out with more confidence when the diagnosis is genuinely uncertain.

Yes, when performed appropriately. The test is conducted in a monitored setting by trained staff who watch your breathing and lung function closely throughout, and a fast-acting bronchodilator is immediately available to reverse any airway narrowing the test provokes. The test is intentionally designed to produce only a temporary, reversible response.

The test is not appropriate for everyone. Significant baseline airflow limitation, a recent heart attack or stroke, uncontrolled high blood pressure, or certain other medical conditions can make the test inappropriate or require extra precautions. Your physician screens for these factors before ordering the test.

You will typically be asked to avoid certain inhaled medications, caffeine, and vigorous exercise for a period of time before the test, since these can affect the result. Always follow the specific instructions given by the office that ordered your test, since requirements can vary.

They evaluate different things. The methacholine challenge test measures how reactive your airways are to a provoking substance, while FeNO testing measures a marker of a specific type of airway inflammation in your exhaled breath. Both can support an asthma evaluation, but neither replaces the other, and your physician chooses which tests fit your specific clinical picture.